Putting the Horse before the CAR–T! Educating Nurses on Algorithms to Recognize Cytokine Release Syndrome and CAR–T Related Encephalopathy Syndrome (203)

3:30 – 4:30 pm Thursday, September 13

1CNE  Chimeric antigen receptor (CAR) therapies, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of hematologic malignancies in pediatric and adult populations, offer remarkable promise for patients with previously treated-refractory disease. Kymriah™, the first FDA-approved agent for the treatment of children and young adults up to 25 years of age with relapsed or refractory B–cell acute lymphoblastic leukemia, demonstrates an overall remission rates 83%. Significant, potentially life-threatening toxicities accompany these promising outcomes, most notably cytokine release syndrome (CRS) and CAR–related encephalopathy syndrome (CRES). Early identification and strategic management of symptoms are critical to support positive patient outcomes. An interprofessional team developed evidence-based algorithms for the diagnosis and management of CAR therapy-related toxicities.

This session presents the content and design of these algorithms their application to practice with now FDA-approved CAR therapies. Content highlights the fundamental role of clinical and advanced practice nurses in the early recognition of symptoms and interprofessional collaboration for grading and management. The session will focus on the application of these algorithms to patient care scenarios, particularly on how various symptom presentations can be assessed and managed to improve patient outcomes during CAR therapy. A case study will be presented to highlight toxicity presentation, nurse assessment, and application of the algorithms to manage these presentations.